Raptor Pharmaceuticals Corp. (RPTP)
-NasdaqGM | Prev Close: | 6.51 |
|---|
| Open: | N/A |
|---|
| Bid: | 5.51 x 2000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 11.25 |
|---|
| Beta: | 0.12 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 4.35 - 7.67 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 698,100 |
|---|
| Market Cap: | 360.86M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.84 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Thu, May 9)
- Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial ResultsGlobeNewswire(Wed, May 8)
- RAPTOR PHARMACEUTICAL CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- 3 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 7)
- Raptor licenses IP for Rett Syndrome from French Research Instituteat theflyonthewall.com(Tue, May 7)
- Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome From French Research InstitutesGlobeNewswire(Tue, May 7)
- This Week in Biotechat Motley Fool(Sat, May 4)
- Two Different Outlooks for Two Tuesday Performersat Motley Fool(Thu, May 2)
- Raptor Pharmaceuticals downgraded to Neutral from Outperform at Wedbushtheflyonthewall.com(Thu, May 2)
- Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic CystinosisPR Newswire(Wed, May 1)
- Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, May 1)
- RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Wed, May 1)
- 3 Healthcare Stock Stories For Tuesday Portfolio Wellnessat Wall St. Cheat Sheet(Wed, May 1)
- Raptor's FDA Approval Is New Test For Orphan Drug Pricingat TheStreet(Wed, May 1)
- Why Raptor Pharmaceuticals Shares Spiked and Then Droppedat Motley Fool(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.08 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.30 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. It engages in the research, manufacture, and commercialization of medicines to treat nephropathic cystinosis, non-alcoholic steatohepatitis (N...
View More 
0.12%